15mg Librela Solution for Dogs - 2 Vials
370940
15mg Librela is an innovative drug for the alleviation of pain associated with osteoarthritis in dogs.
Librela 15mg is a revolutionary solution that provides effective relief from osteoarthritis pain in dogs, with a safety profile supported by studies. It differs from traditional NSAIDs by specifically targeting Nerve Growth Factor (NGF), an essential cause of osteoarthritis pain.
Librela is a refrigerated medication - We will send it via Royal Mail Special Delivery using insulated packaging and ice packs. A signature is required on delivery and it must be put straight into a fridge. We cannot guarantee same day dispatch for orders placed after 12pm. VETERINARY PRESCRIPTION REQUIRED.
Librela is a monoclonal antibody, replicating the function of naturally occurring antibodies. It is removed via standard protein degradation pathways, resulting in a low-impact treatment on the liver or kidneys and minimal gastrointestinal effects. Clinical studies indicate increased mobility and reduced pain in dogs after the initial Librela injection.
Product Features
- Pack Size: - Pack of 2
- Target Animal: - Dog (Canine)
- Related Condition: - Osteoarthritis in Dogs
- Pet Prescription Required?: - Yes
- Active Ingredient: - Bedinvetmab
- Product Name: - Librela solution for injection for dogs
More Information
Description
Administered as a monthly injection in a clinic or at home, Librela simplifies the management of osteoarthritis pain. With no known interactions with other medications, it was well-tolerated in studies when co-administered with common medications, including RIMADYL®.
15mg Librela, a versatile solution, can be stopped or started for quick pain relief, ideal for long-term management of osteoarthritis pain. It offers a unique approach for both peri-operative pain and osteoarthritis pain and inflammation.
Recommended for dogs as young as six weeks, it is an option for pet owners preferring a monthly injection, dogs who don't tolerate NSAIDs, or dogs who may have difficulty taking oral medications.
Recognising that canine osteoarthritis is common, affecting 4 out of every 10 dogs, Librela provides an opportunity to enhance the quality of life and mobility for dogs suffering from osteoarthritis pain. Early screening and proactive education can ensure more dogs benefit from this breakthrough treatment, improving their quality of life.
Each vial of 1ml Librela contains 15mg bedinvetmab. 15mg Librela is a caninised monoclonal antibody.
Librela is used for the alleviation of pain associated with osteoarthritis in Dogs.
Dosage and administration
Librela is for subcutaneous use. The recommended dose of Librela is 0.5-1.0 mg/kg bodyweight, once a month.
For dogs weighing <5.0 kg aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously. For dogs between 5 and 60 kg administer the entire content of the vial (1ml) according to the dose prescribed by your Vet. For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2ml).
Contra-indications, warnings, etc.
Do not use Librela in cases of hypersensitivity to the active substance or to any of the excipients. Do not use Librela in dogs under 12 months. Do not use Librela in animals intended for breeding. Do not use Librela in pregnant or lactating animals.
Librela may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect or may result in a decrease in efficacy in animals that responded to treatment previously. If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments. The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs. Laboratory studies with anti-NGF antibodies in cynomolgus monkeys have shown evidence of teratogenic and foetotoxic effects. In a laboratory study over a 2-week period in young, healthy dogs without osteoarthritis, this veterinary medicinal product had no adverse effect when concomitantly administered with a non-steroidal anti-inflammatory product (carprofen). There are no safety data on the concurrent long-term use of NSAIDs and Librela in dogs. In clinical trials in humans, rapidly progressive osteoarthritis has been reported in patients receiving humanised anti-NGF monoclonal antibody therapy. The incidence of these events increased with high doses and in those human patients that received long-term (more than 90 days) non-steroidal anti-inflammatory drugs (NSAIDs) concomitantly with an anti-NGF monoclonal antibody. Dogs have no reported equivalent of human rapidly progressive osteoarthritis. No other laboratory studies on the safety of concomitant administration of this veterinary medicinal product with other veterinary medicinal products have been conducted. No interactions were observed in field studies where this veterinary medicinal product was administered concomitantly with veterinary medicinal products containing parasiticides, antimicrobials, topical antiseptics with or without corticosteroids, antihistamines and vaccines. If a vaccine(s) is to be administered at the same time as treatment with this veterinary medicinal product, the vaccine(s) should be administered at a different site to that of Librela’s administration, to reduce any potential impact on immunogenicity of the vaccine. Do not mix with any other veterinary medicinal product. Mild reactions at the injection site (e.g. swelling and heat) may uncommonly be observed. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). No adverse reactions, except mild reactions at the injection site, were observed in a laboratory overdose study when Librela was administered for 7 consecutive monthly doses at10 times the maximum recommended dose. In case of adverse clinical signs after an overdose the dog should be treated symptomatically. User warnings Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Repeated self-administration may increase the risk of hypersensitivity reactions. The importance of Nerve Growth Factor in ensuring normal foetal nervous system development is well-established and laboratory studies conducted on non-human primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity. Pregnant women, women trying to conceive and breastfeeding women should take extreme care to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Pharmaceutical precautions
Store Librela in a refrigerator (2°C - 8°C). Do not freeze. Store in the original package. Protect from light. Shelf life after first opening the immediate packaging: use immediately Keep out of the sight and reach of children. For animal treatment only.
Legal category:
Librela is a POM-V (Pet Prescription Required)
You may also like
BD Discardit 2ml Syringe with 21g Needle - each
2ml Syringe complete with 21 gauge needle. Suitable for injection of Librela, Cytopoint, Solensia etc.
